0000950170-23-018401.txt : 20230505 0000950170-23-018401.hdr.sgml : 20230505 20230505180056 ACCESSION NUMBER: 0000950170-23-018401 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230503 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 23895281 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER NAME: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4 1 ownership.xml 4 X0407 4 2023-05-03 0001840229 MiNK Therapeutics, Inc. INKT 0001098972 AGENUS INC 3 FORBES ROAD LEXINGTON MA 02421 false false true false false Common Stock 2023-05-03 4 P false 128689 1.0789 A 21473374 D Common Stock 2023-05-04 4 P false 21473 1.2223 A 21494847 D Common Stock 2023-05-05 4 P false 100000 0.9485 A 21594847 D Common Stock 2023-05-05 4 P false 200 1.25 A 21595047 D Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20). Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25). On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close. /s/ Christine Klaskin, Vice President, Finance 2023-05-05